Features of mental disorders and their correction in patients with cardiac pathology

Abstract

In everyday practice, the doctor rarely encounters only one specific disease, more often a patient with comorbid pathology comes to him. Such a group of concomitant diseases are mental disorders. Their prevalence in cardiology practice reaches 80%. Mood affective, anxiety and somatization disorders, as well as cognitive impairment are observed most often. The review looked at mental disorders that occur in cardiac diseases with the highest number of deaths, such as coronary heart disease, including myocardial infarction and cardiac arrhythmias, arterial hypertension and cerebrovascular diseases. Including attention is paid to the senile asthenia syndrome, which is accompanied by cognitive impairment, loss of previous vital interests and depression. The review highlights the questions of re­gular and adequate psychopharmacotherapy of cardiovascular diseases, which leads to a statistically significant decrease in the frequency of their exacerbations, which reduces the number of doctors who come to see for somatoge­nic symptoms, and also allows to improve the prognosis of the underlying disease and significantly reduce mortality. It was observed that the doctor should take into account the fact that modern cardiological preparations have effects that can cause side effects in the form of mental disorders when choosing a therapy. Understanding the processes of formation and occurrence of mental diseases in a patient with cardiovascular pathology, as well as methods for their correction, can increase the effectiveness of the therapy and improve the prognosis of the underlying disease.

Keywords

cardiovascular disease / mental illness / psychopharmacotherapy

References

[1] Sharabchiev Yu.T., Antipov V.V., Antipova S.I. Comorbidity is an actual scientific and practical problem of the 21st century medicine. Meditsinskie novosti. 2014; (8): 6–11. (In Russ.)

[2] Шарабчиев Ю.Т., Антипов В.В., Антипова С.И. Коморбидность — актуальная научная и научно-практическая проблема медицины ХХI века. Мед. новости. 2014; (8): 6–11.

[3] Oganov R.G., Denisov I.N., Simanenkov V.I. et al. Comorbidities in practice. Clinical guidelines. Kardiovaskulyarnaya terapiya i profilaktika. 2017; 16 (6): 5–56. (In Russ.) DOI: 10.15829/1728-8800-2017-6-5-56.

[4] Оганов Р.Г., Денисов И.Н., Симаненков В.И. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваск. терап. и профил. 2017; 16 (6): 5–56. DOI: 10.15829/1728-8800-2017-6-5-56.

[5] Chazova I.E. The experience of dealing with cardiovascular diseases in Russia. Analiticheskiy vestnik. 2015; (44): 4–8. (In Russ.)

[6] Чазова И.Е. Опыт борьбы с сердечно-сосудистыми заболеваниями в России. Аналитич. вестн. 2015; (44): 4–8.

[7] Andryushchenko A.V. Prevalence and structure of mental disorders in general medicine. Psikhicheskie rasstroystva v obshchey meditsine. 2011; 1: 14–27. (In Russ.)

[8] Андрющенко А.В. Распространённость и структура психических расстройств в общей медицине. Психич. расстройства в общей мед. 2011; 1: 14–27.

[9] Roxanne T., Nicholas D.G., Mudassar B.H. et al. The burden and trends of psychiatric co-morbidities amongst patients with cardiomyopathy. Int. J. Cardiol. 2014; 398–399. DOI: 10.1016/j.ijcard.2014.04.062.

[10] Ponikowski P., Voors A., Anker S. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart fai­lure. Eur. Heart J. 2016; 37 (27): 2129–2200. DOI: 10.1093/eurheartj/ehw128.

[11] Ponikowski P., Voors A., Anker S. et al. Клинические рекомендации. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности. Рос. кардиол. ж. 2017; (1): 7–81. DOI: 10.1093/eurheartj/ehw128.

[12] Obshcherossiyskay aobshchestvennaya organizatsiya “Rossiyskaya assotsiatsiya gerontologov i geriat­rov”. Starcheskaya asteniya. Klinicheskie rekomendatsii. (Clinical recommendations. Senile asthenia. All-Russian Public Organization “Russian Association of Gerontologists and Geriatricians”.) 2018; 157 p. (In Russ.)

[13] Общероссийская общественная организация «Российская ассоциация геронтологов и гериатров». Старческая астения. Клинические рекомендации. 2018; 157 с.

[14] Chow C.K., Teo K.K., Rangarajan S. et al. Preva­lence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013; 310 (9): 959–968. DOI: 10.1001/jama.2013.184182.

[15] Kearney P.M., Wbelton M., Reynolds K. et al. Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 2004; 22 (1): 11–19. DOI: 10.1097/01.hjh.0000098149.7095679.

[16] Hajjar J., Kotcben T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003; 290 (2): 199–206. DOI: 10.1001/jama.290.2.199.

[17] Ayvazyan T.A. Basic principles of psychocorrection in hypertensive disease. ­Atmosfera. Novosti kardiologii. 2002; (1): 5–7. (In Russ.)

[18] Айвазян Т.А. Основные принципы психокоррекции при гипертонической болезни. Атмосфера. Новости кардиологии. 2002; (1): 5–7.

[19] Laine H., Katoh C., Luotolahti M. et al. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation. 1999; 100: 2425–2430. DOI: 10.1161/01.cir.100.24.2425.

[20] Blagovidova O.B., Mikhaylov V.I., Ostrovskiy A.B., Gubanov A.V. Correction of psychosomatic disorders in hypertension. Aktualʹnye problemy psikhiatrii, narkologii i nevrologii. Sbornik nauchnykh trudov. Moskva — Khabarovsk, 1998; 70–75. (In Russ.)

[21] Благовидова О.Б., Михайлов В.И., Островский А.Б., Губанов А.В. Коррекция психосоматических нарушений при гипертонической болезни. Актуальные проблемы психиатрии, наркологии и неврологии. Сб. научн. тр. М. — Хабаровск, 1998; 70–75.

[22] Lasnier C., Marey C., Lapeyre G. et al. Cardiovascular tolerance to tianeptine. PresseMed. 1991; 20 (37): 1858–1863. (In French). PMID: 1836619.

[23] Nedostup A.V., Fedorova V.I., Linevich A.Yu. et al. Anxiodepressive and neuromediatory disorders in hypertensive patients. Effects of cypramil the­rapy. Terapevticheskiy arkhiv. 2005; (11): 55–62. (In Russ.)

[24] Недоступ А.В., Фёдорова В.И., Линевич А.Ю. и др. Тревожно-депрессивные и нейромедиаторные нарушения у больных гипертонической болезнью, влияние на них терапии ципрамилом. Терапевтический архив. 2005; (11): 55–62.

[25] Skoog I., Lernfelt B., Landahl S. et al. 15 year longitudinal study of blood pressure and dementia. Lancet. 1996; 347 (9009): 11301. DOI: 10.1016/s0140-6736(96)90608-x.

[26] Shishkova V.N. Prevention of dementia in patients with arterial hypertension. Trudnyy patsient. 2014; (4): 26–32. (In Russ.)

[27] Шишкова В.Н. Профилактика деменции у пациентов с артериальной гипертензией. Трудный пациент. 2014; (4): 26–32.

[28] Elias M.F., Wolf P.A., D`Agostino R.B. et al. Untreated blood pressure level is inversely reated to cognitive functioning: the Framingham Study. Am. J. Epide­miol. 1993; 138 (6): 353–364. DOI: 10.1093/oxfordjournals.aje.a116868.

[29] Tzourio C., Dufouil C., Ducimetiere P. et al. Cognitive decline in individuals with high blood pressure: a longi­tudinal study in the elderly. EVA Study Group. Epidemiol. Vasc. Aging. Neurol. 1999; 53 (9): 1948–1952. DOI: 10.1212/wnl.53.9.1948.

[30] Ruitenberg A., Skoog I., Ott A. et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement. Geriatr. Cogn. Di­sord. 2001; 12 (1): 33–39. DOI: 10.1159/000051233.

[31] Launer L.J., Masaki K., Petrovitch H. et all. The association between midlife blood pressure level and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995; 274 (23): 1846–1851. DOI: 10.1016/s0197-4580(00)00096-8.

[32] Gorelick P.B., Scuteri A., Black S.E. et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011; 42 (9): 2672–2713. DOI: 10.1161/STR.0b013e318229949.

[33] Pogosova G.V. Depression — A novel risk factor of ischemic heart disease and predictor of coronary death. Kardiologiya. 2002; (4): 86–90. (In Russ.)

[34] Погосова Г.В. Депрессия — новый фактор риска ишемической болезни сердца и предиктор коронарной смерти. Кардиология. 2002; (4): 86–90.

[35] Ushkalova E.A., Ushkalova A.V. Efficacy and safety of antidepressants in cardiac patients. Prakticheskaya angiologiya. 2006; (3): 28–32. (In Russ.)

[36] Ушкалова Е.А., Ушкалова А.В. Эффективность и безопасность антидепрессантов у кардиологических больных. Практич. ангиол. 2006; (3): 28–32.

[37] Krasnov V.N. Depression and cardiovascular di­sease. Praktikuyushchiy vrach segodnya. 2002; (2): 31–32. (In Russ.)

[38] Краснов В.Н. Депрессии и сердечно-сосудистые заболевания. Практикующий врач сегодня. 2002; (2): 31–32.

[39] World Health Organization. World Health Report. New York. 2001. https://apps.who.int/iris/handle/10665/89126 (access data: 01.09.2019). (In Russ.)

[40] Всемирная организация здравоохранения. Доклад о состоянии здравоохранения в мире. Нью-Йорк. 2001. https://apps.who.int/iris/handle/10665/89126 (дата обращения: 01.09.2019).

[41] Kotov A.M., Stotskiy A.D., Kolesnikov D.B. Antidepressants in cardiology. Klinicheskaya meditsina. 2012; (10): 11–16. (In Russ.)

[42] Котов А.М., Стоцкий А.Д., Колесников Д.Б. Антидепрессанты в кардиологии. Клин. мед. 2012; (10): 11–16.

[43] Lowe G.D., Lee A.J., Rumley A. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Brit. J. Haematol. 1997; 96 (1). 168–173. DOI: 10.1046/j.1365-2141.1997.8532481.x.

[44] Scherrer J.F., Xian H., Bucholz K.K. A twin study of depression symptoms, hypertension, and heart disease in middle-aged men. Psychosomat. Med. 2003; 65 (4): 548–557. DOI: 10.1097/01.psy.0000077507.29863.cb.

[45] Baghai T.C. Polymorphisms in the angiotensin converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol. Psychiatry. 2006; 11: 1003–1015. DOI: 10.1038/sj.mp.4001884.

[46] Galyautdinov G.S., Lonkin M.A. Cognitive impairment in chronic heart failure. Vestnik sovremennoy klinicheskoy meditsiny. 2015; 8 (1): 69–77. (In Russ.)

[47] Галяутдинов Г.С., Лонкин М.А. Когнитивные нарушения при хронической сердечной недостаточности. Вестн. соврем. клин. мед. 2015; 8 (1): 69–77.

[48] Kirchhof P., Benussi S., Kotecha D. et al. ESC guidelines for the management of at­rial fibrillation developedin collaboration with EACTS. Eur. J. Cardiothorac. Surg. 2016; 50 (5): e1–e88. Epub 2016 Sep. 23. (Russ. Ed.: Rekomendatsii ESC po le­cheniyu patsientov s fibrillyatsiey predserdiy, razrabotannye sovmestno s EACTS. Rossiyskiy kardiologicheskiy zhurnal. 2017; (7): 7–86 (In Russ.)

[49] Kirchhof P., Benussi S., Kotecha D. et al. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Рос. кардиол. ж. 2017; (7): 7–86. DOI: 10.15829/1560-4071-2017-7-7-86.

[50] Kang Y. Effect of uncertainty on depression in patients with newly diagnosed atrial fibrillation. Prog. Cardiovasc. Nurs. 2006; 21 (2): 83–87. DOI: 10.1111/j.0889-7204.2006.04810.x.

[51] Medvedev V.E., Zverev K.V., Epifa­nov A.V. Psychosomatic correlations in atrial fibrillations. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2011; 3 (4): 45–49. (InRuss.)

[52] Медведев В.Е., Зверев К.В., Епифанов А.В. Психосоматические корреляции при фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2011; 3 (4): 45–49.

[53] Markov V.A., Maksimov I.V., Rya­bov V.V. et al. New points of view acute coronary syndrome treatment. Sibirskiy meditsinskiy zhurnal (Tomsk). 2007; (3): 10–16. (In Russ.)

[54] Марков В.А., Максимов И.В., Рябов В.В. и др. Разработка и внедрение новых методов лечения острого коронарного синдрома. Сибирский мед. ж. (Томск). 2007; (3): 10–16.

[55] Bankier B., Januzzi J.L., Littman A.B. The high prevalence of multiple psychiatric disorders in stable outpatients with coronary heart disease. Psychosom. Med. 2004; 66: 645–650. DOI: 10.1097/01.psy.0000138126.90551.62.

[56] Polikarpov L.S., Derevyannykh E.V., Yaskevich R.A. et al. Effect of phena­zepam on anxiety, depression, sleep quality, and cardiac arrhythmias in patients with acute myocardial infarction. Sibirskiy meditsinskiy zhurnal (Tomsk). 2012; 27 (2): 45–49. (In Russ.)

[57] Поликарпов Л.С., Деревянных Е.В., Яскевич Р.А. и др. Влияние препарата феназепама на уровень тревоги и депрессии, показатели сна, нарушение ритма сердца у больных острым инфарктом миокарда. Сибирский мед. ж. (Томск). 2012; 27 (2): 45–49.

[58] Lesperance F., Frasure S.N., Talajic M. et al. Five year risk of cardiac mortality in relation to initial severity and one year changes in depression symptoms after myocardial infarction. Circulation. 2002; 105: 1049–1053. DOI: 10.1016/S1062-1458(02)00771-7.

[59] O’Connor C.M., Glassman A.H., Harrison D.J. Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. J. Clin. Psychiatry. 2005; 66: 346–352. DOI: 10.4088/jcp.v66n0311.

[60] Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937–952. DOI: 10.1016/S0140-6736(04)17018-9.

[61] Smulevich A.B. Depression in cardiovascular diseases. Psikhicheskie rasstroystva v obshchey meditsine. 2013; (4): 4–9. (In Russ.)

[62] Смулевич А.Б. Депрессии при сердечно-сосудистых заболеваниях. Психич. расстройства в общей мед. 2013; (4): 4–9.

[63] Mazza M., Lotrionte M., Biondi-Zoccai G. Selective serotonin reuptake inhibitors provide significant lo­wer re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analy­sis. J. Psychopharmacol. 2010; 24 (12): 85–92. DOI: 10.20996/1819-6446-2012-8-1-45-50.

[64] Vihang N.V. American Psychiatric Association. Diag­nostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association. 2000; 255 p.

[65] Grinberg M.L., Gabinskiy Ya.L. Acute psychoses in reani­mation period of acute myocardial infarction treatment. Kardiovaskulyarnaya terapiya i profilaktika. 2006; 5 (7): 50–55. (In Russ.)

[66] Гринберг М.Л., Габинский Я.Л. Острые психозы в реанимационном периоде лечения инфаркта миокарда. Кардиоваск. терап. и профил. 2006; 5 (7): 50–55.

[67] Maksimov A.I. Delirium in the acute period of Q-myocardial infarction. Sibirskiy meditsinskiy zhurnal (Tomsk). 2011: 26 (1-1): 58–63. (In Russ.)

[68] Максимов А.И. Делирий в остром периоде Q-инфаркта миокарда. Сибирский мед. ж. (Томск). 2011: 26 (1): 58–63.

[69] Zabolotskikh I.B., Pesnyak E.V. Sedatsiya v intensivnoy terapii. (Sedation in intensive care.) Petrozavodsk: IntelTek. 2007; 79 p. (In Russ.)

[70] Заболотских И.Б., Песняк Е.В. Седация в интенсивной терапии. Петрозаводск: ИнтелТек. 2007; 79 с.

[71] Kuznetsov Yu.A. Clinic and treatment of mental disorders in the acute period of myocardial infarction. Klinicheskaya meditsina. 1982; (7): 75–77. (In Russ.)

[72] Кузнецов Ю.А. Клиника и лечение психических расстройств в остром периоде инфаркта миокарда. Клин. мед. 1982; (7): 75–77.

[73] Trubnikov G.V., Zorina Z.N. Acute psychosis in myocardial infarction. Kardiologiya. 1973; (9): 76–81. (In Russ.)

[74] Трубников Г.В., Зорина З.Н. Острые психозы при инфаркте миокарда. Кардиология. 1973; (9): 76–81.

[75] Trzepacz P., Breitbart W., Franklin J.H. et al. Ameri­can Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am. J. Psychiatry. 1999; 156: 1–20.

[76] Ouimet S., Kavanagh B.P., Gottfried S.B. et al. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2007; 33: 66–73. DOI: 10.1007/s00134-006-0399-8.

[77] Brilakis E.S., Mavrogiorgos N.C., Kopecky S.L. et al. Validation of the TIMI risk score for ST-elevation acute myocardial infarction in a community-based coronary care unit registry. Circulation. 2001; 104: 380.

[78] Schwartz M., Moalem G., Leibowitz-Amit R., Cohen I.R. Innate and adaptive immune responses can be be­neficial for CNS repair. Trends Neurosci. 1999; 22: 295–299. DOI: 10.1016/s0166-2236(99)01405-8.

[79] Kokaia Z., Martino G., Schwartz M., Lindvall O. Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat. Neurosci. 2012; 15: 1078–1087. DOI: 10.1038/nn.3163.

[80] Orekhov A., Oishi Y., Nikiforov N. et al. Transciptome analysis revealed inflammatory genes responsible for foam cell formation. Atherosclerosis. 2018; 275: 116. DOI: 10.1016/j.atherosclerosis.2018.06.329.

[81] Smith R.S. The macrophage theory of depression. Med. Hypotheses. 199; 35: 298–306.

[82] Wium-Andersen M.K., Orsted D.D., Nielsen S.F., Nordestgaard B.G. Elevated C-reactive protein levels, psychological distress, and depression in 73,131 individuals. JAMA Psychiatry. 2013; 70: 176–184. DOI: 10.1016/S0924-9338(12)75652-3.

[83] Dahl J., Ormstad H., Aass H.C. et al. The plasma levels of various cytokines are increased during on­going depression and are reduced to normal levels after reco­very. Psychoneuroendocrinology. 2014; 45: 77–86. DOI: 10.1016/j.psyneuen.2014.03.019.

[84] IL]-6, tumour necrosis factor alpha [TNF-alpha

[85] Liu Y., Ho R.C., Mak A. Interleukin -6, tumour necrosis factor alpha and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a metaanalysis and meta-regression. J. Affect. Disord. 2012; 139: 230–239. DOI: 10.1016/j.jad.2011.08.003.

[86] Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009; 71: 171–186. DOI: 10.1097/PSY.0b013e3181907c1b.

[87] Baranov A.A., Denisov I.N., Chuchalin A.G. et al. Rukovodstvo po pervichnoy mediko-sanitarnoy pomoshchi. (Primary Health Care Guide.) М.: GEOTAR-Media. 2006; 1541 p. (In Russ.)

[88] Баранов А.А., Денисов И.Н., Чучалин А.Г. и др. Руководство по первичной медико-санитарной помощи. М.: ГЭОТАР-Медиа. 2006; 1541 с.

[89] Smulevich A.B., Medvedev V.Eh. Terapiya psikhiches­kikh rasstroystv u bol'nykh s infarktom miokarda. In: Syrkin A.L., Novikova N.A., Terekhin S.A. Ostryy koronarnyy sindrom. (Therapy of mental disorders in patients with myocardial infarction. In: Syrkin A.L., Novikova N.A., Terekhin S.A. Acute coronary syndrome.) М.: MIA. 2010; 333–347. (In Russ.)

[90] Смулевич А.Б., Медведев В.Э. Терапия психических расстройств у больных с инфарктом миокарда. В кн.: Сыркин А.Л., Новикова Н.А., Терёхин С.А. Острый коронарный синдром. М.: МИА. 2010; 333–347.

[91] Ionov M.V., Zvartau N.Eh., Konradi A.O. First look at new 2018 joint ESH/ESC Guidelines on diagnosis and management of hypertension. Arterial hypertension. 2018; 24 (3): 351–358. (In Russ.) DOI: 10.18705/1607-419X-2018-24-3-351-358.

[92] Ионов М.В., Звартау Н.Э., Конради А.О. Сов­местные клинические рекомендации ESH/ESC 2018 по диагностике и ведению пациентов с артериальной гипертензией: первый взгляд. Артериальная гипертензия. 2018; 24 (3): 351–358. DOI: 10.18705/1607-419X-2018-24-3-351-358.

[93] Russian Cardiology Society, National Society for the Study of Atherosclerosis. Clinical recommendations. Stable ischemic heart disease. 2016; 56 p. (In Russ.)

[94] Российское кардиологическое общество, Национальное общество по изучению атеросклероза. Клинические рекомендации. Стабильная ишемическая болезнь сердца. 2016; 56 с.

[95] Vasyuk Yu.A., Dovzhenko T.V. Diagnostika i lechenie depressiy pri zabolevaniyakh serdechno-sosudistoy sistemy. (Diagnosis and treatment of depression in diseases of the cardiovascular system.) Uchebnoe posobie. М.: Anakharsis. 2006; 58 р. (In Russ.)

[96] Васюк Ю.А., Довженко Т.В. Диагностика и лечение депрессий при заболеваниях сердечно-сосудистой системы. Учеб. пособие. М.: Анахарсис. 2006; 58 с.

[97] Vasyuk Yu.A., Dovzhenko T.V., Shkolʹnik E.L., Yu­shchuk E.N. Depressiya i khronicheskaya serdechnaya nedostatochnostʹ pri serdechno-sosudistykh zabolevaniyakh. (Depression and chronic heart failure in cardiovascular di­seases.) М.: Anakharsis. 2006; 112 р. (In Russ.)

[98] Васюк Ю.А., Довженко Т.В., Школьник Е.Л., Ющук Е.Н. Депрессия и хроническая сердечная недостаточность при сердечно-сосудистых заболеваниях. Учеб. пособие. М.: Анахарсис. 2006; 112 с.

[99] Vasyuk Yu.A., Dovzhenko T.V., Shkolʹnik E.L., Yu­shchuk E.N. Depressivnye i trevozhnye rasstroĭstva v kardiologii. (Depressive andanxiety disorders in cardiology.) 2nd ed. М.: Anakharsis. 2009; 200 р. (In Russ.)

[100] Васюк Ю.А., Довженко Т.В., Школьник Е.Л., Ющук Е.Н. Депрессивные и тревожные расстройства в кардиологии. 2-е изд. М.: Анахарсис. 2009; 200 с.

[101] Belousov Yu.B., Kukes V.G., Lepakhin V.K., Petrov V.I. Klinicheskaya farmakologiya. Natsionalʹnoe rukovods­tvo. (Clinical pharmacology. National guide.) М.: ­GEOTAR-Media. 2014; 976 p. (In Russ.)

[102] Белоусов Ю.Б., Кукес В.Г., Лепахин В.К., Петров В.И. Клиническая фармакология. Национальное руководство. М.: ГЭОТАР-Медиа. 2014; 976 с.

[103] Rumyantseva G.M., Milopolʹskaya I.M., Grushkov A.V. et al. The effectiveness of Tanakan treatment of patients with borderline level psycho-organic syndrome who have received various doses of ionizing radiation in the past. Rossiyskiy psikhiatricheskiy zhurnal. 1999; (1): 31–36. (In Russ.)

[104] Румянцева Г.М., Милопольская И.М., Грушков А.В. и др. Эффективность лечения препаратом танакан больных с психоорганическим синдромом пограничного уровня, получивших в прошлом различные дозы ионизирующего облучения. Рос. психиатрич. ж. 1999; (1): 31–36.

[105] Vasyuk Yu.A., Dovzhenko T.V., Nesterova E.A. et al. Influence of combined antihypertensive and antidepressant therapy on left ventricular remodeling in patients with arterial hypertension, anxiety and depression. Ratsionalʹnaya farmakoterapiya v kardiologii. 2008; (3): 76–82. (In Russ.) DOI: 10.20996/1819-6446-2008-4-3-76-82.

[106] Васюк Ю.А., Довженко Т.В., Нестерова Е.А. и др. Особенности ремоделирования левого желудочка у больных артериальной гипертонией с тревожно-депрессивными расстройствами на фоне комбинированной терапии гипотензивными препаратами и антидепрессантами. Рациональн. фармакотерап. в кардиол. 2008; (3): 76–82. DOI: 10.20996/1819-6446-2008-4-3-76-82.

[107] Kharkevich D.A. Farmakolo­giya. (Pharmacology.) 10nd ed. М.: ­GEOTAR-Media. 2010; 908 p. (In Russ.)

[108] Харкевич Д.А. Фармакология. 10-е изд. М.: ­ГЭОТАР-Медиа. 2010; 908 с.

[109] Pogosova G.V. Psychoemotional disorders in cardiovascular diseases. Therapeutic aspects. Consilium medicum. 2006; 8 (5): 118–123. (In Russ.)

[110] Погосова Г.В. Психоэмоциональные расстройства при сердечно-сосудистых заболеваниях. Терапевтические аспекты. Consil. med. 2006; 8 (5): 118–123.

[111] Oganov R.G., Pogosova G.V., Shalʹnova S.A., Deev A.D. Depressive disorders in general medical practice in ­KOMPAS Study: Outlook of a cardiologist. Kardiologiya. 2005; 45 (8): 37–43. (In Russ.)

[112] Оганов Р.Г., Погосова Г.В., Шальнова С.А., Деев А.Д. Депрессивные расстройства в общемедицинской практике по данным исследования КОМПАС: взгляд кардиолога. Кардиология. 2005; 45 (8): 37–43.

[113] Smulevich A.B. Depressii v obshchemeditsinskoy praktike. (Depression in general medical practice.) M.: MIA. 2000; 256 р. (In Russ.)

[114] Смулевич А.Б. Депрессии в общемедицинской практике. М.: МИА. 2000; 256.

[115] Balu­nov O.A., Zakharov D.V., Mokshantsev P.S. et al. Treatment of post-stroke depression in the early recovery period: experience with sertraline. Klinicheskaya farmakologiya i terapiya. 2005; 14 (2): 90–92. (In Russ.)

[116] Балунов О.А., Захаров Д.В., Мокшанцев П.С. и др. Лечение постинсультной депрессии в раннем восстановительном периоде: опыт применения сертралина. Клин. фармакол. тер. 2005; 14 (2): 90–92.

[117] Glassman A.H., O’Connor C.M., Califf R.M. et al. Sertraline treatment of major depression in patient with acute MI or unstable angina. JAMA. 2002; 288: 701–709. DOI: 10.1001/jama.288.6.701.

[118] Andrusenko M.P., Shishenin V.S., Yakovleva O.B. The use of tianeptine in the treatment of late-life depression. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 1999; 99 (2): 25–30. (In Russ.)

[119] Андрусенко М.П., Шишенин В.С., Яковлева О.Б. Использование тианептина при лечении поздних депрессий. Ж. неврол. и психиатрии им. С.С. Корсакова. 1999; 99 (2): 25–30.

[120] Ganau A., Devereux R.B., Roman M.J. et al. Patterns of left ventricular hypertrophy and geometric remo­deling in essen tial hypertension. J. Am. Coll. Cardiol. 1992; 19: 1550–1558. DOI: 10.1016/0735-1097(92)90617-v.

[121] Finch S.J., van Zyl L.T. Cardioversion of persistent atrial arrhythmia after treatment with venlafaxine in successful management of major depression and posttrauma­tic stress disorder. Psychosomatics. 2006; 47 (6): 533–536. DOI: 10.1176/appi.psy.47.6.533.

[122] Shirayama T., Sakamoto T., Sakatani T. et al. Usefulness of paroxetine in depressed men with paroxysmal atrial fibrillation. Am. J. Cardiol. 2006; 97: 1749–1751. DOI: 10.1016/j.amjcard.2006.01.038.

[123] Roose S.P., Spatz E. Treating depression in patients with ischaemic heart disease: which agents are best to use and to avoid? New York: College of Physicians and Surgeons, Columbia University. 1999; 60 (9): 2674. DOI: 10.2165/00002018-199920050-00006.

[124] McFarlane A., Kamath M.V., Fallen E.L. et al. Effect of sertraline on the recovery rate of cardiac autono­mic function in depressed patients after acute myocar­dial infarction. Am. Heart J. 2001; 142 (4): 617—623. DOI: 10.1067/mhj.2001.116766.

[125] Starchina Yu.A., Parfenov V.A., Chazova I.E. et al. Cognitive functions and emotional state of stroke patients with antihypertensive therapy. Zhurnal nevrologii i psikhiatrii. im. S.S. Korsakova. Insulʹt. 2005; (15): 39–44. (In Russ.)

[126] Старчина Ю.А., Парфёнов В.А., Чазова И.Е. и др. Когнитивные функции и эмоциональное состояние больных, перенёсших инсульт, на фоне антигипертензивной терапии. Ж. неврол. и психиатрии им. С.С. Корсакова. Инсульт. 2005; (15): 39–44.

[127] Pelisch N., Hosomi N., Ueno M. Blockade of AT-­receptors Pro-1 tects the blood-brain barrier and improves cognition in dahl salt-sensitive hypertensive rats. American Journal of Hypertension. 2011; 24: 362–368. DOI: 10.1038/ajh.2010.241.

[128] PROGRESS Collaborative Group. Randomised ­trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358 (9287): 1033–1041. DOI: 10.1016/S0140-6736(01)06178-5.

[129] Parfenov V.A., Starchina Yu.A. Cognitive impairment and their treatment for arterial hypertension. Nervnye bolezni. 2015; (1): 16–22. (In Russ.)

[130] Парфёнов В.А., Старчина Ю.А. Когнитивные расстройства и их лечение при артериальной гипертонии. Нервные болезни. 2015; (1): 16–22.

[131] Qaseem A., Snow A., Cross T. et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the american college of physicians and the american academy of family physicians. Ann. Intern. Med. 2008; 148: 370–378. DOI: 10.7326/0003-4819-148-5-200803040-00008.

[132] Baskys A., Hou A.C. Vascular dementia: pharmacological treatment approaches and perspectives. Clin. Interv. Aging. 2007; 2 (3): 327–335. PMID: 18044183.

[133] Wilcock G., Möbius H.J., Stöffler A., MMM 500 Group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int. Clin. Psychopharmacol. 2002; 17: 297–305.

[134] Orgogozo J.M., Rigaud A.S., Stöffler A. et al. Efficacy and safety of memantine in patients with mild to mode­rate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002; 33 (7): 1834–1839. DOI: 10.1161/01.str.0000020094.08790.49.

[135] Kavirajan H., Schneider L.S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet. Neurol. 2007; 6 (9): 782–792. DOI: 10.1016/S1474-4422(07)70195-3.

[136] Chen N., Yang M., Guo J. et al. Cerebrolysin for vascular dementia. Cochrane Database Syst. Rev. 2013; (1): CD008900. DOI: 10.1002/14651858.CD008900.pub2.

[137] Wirth Y., Goebel C. Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses ­using realistic definitions of response. Dement. Geriatr. Cogn. Disord. 2014; 37 (1–2): 71–85. DOI: 10.1159/000353801.

[138] Di Santo S.G., Prinelli F., Adorni F. et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J. Alzheimers Dis. 2013; 35 (2): 349–361. DOI: 10.3233/JAD-122140.

[139] Dovzhenko T.V., Maychuk E.Yu. Chest pain in cardiovascular diseases of various origins. Clinical: psychopathological, therapeutic aspects. Russkiy meditsinskiy zhurnal. 2001; (25): 1192–1196. (In Russ.)

[140] Довженко Т.В., Майчук Е.Ю. Кардиалгический синдром при сердечно-сосудистых заболеваниях различного генеза. Клинические: психопатологические, терапевтические аспекты. Русский мед. ж. 2001; (25): 1192–1196.

[141] Aleksandrov A.A. Use of antidepressants in diseases of the cardiovascular system. Kardiologiya v Belarusi. 2009; (1): 75–83. (In Russ.)

[142] Александров А.А. Применение антидепрессантов при заболеваниях сердечно-сосудистой системы. Кардиол. в Беларуси. 2009; (1): 75–83.

[143] Jiang W., Davidson J.R. Antidepressant therapy in patients with ischemic heart disease. Am. Heart J. 2005; 150 (5): 871–881. DOI: 10.1016/j.ahj.2005.01.041.

[144] Mohapatra P.K., Nilamadhab K., Mrutyunjaya B. Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocar­dial infarction: six month prospective study on outcome. Clin. Pract. Epidemiol. Ment. Hlth. 2005; 1: 26. DOI: 10.1186/1745-0179-1-26.

[145] Alamo C., López-Muñoz F., García-García P., García-Ramos S. Risk-benefit analysis of antidepressant drug treatment in the elderly. Psychogeriatrics. 2014; 14 (4): 261–268. DOI: 10.1111/psyg.12057.

[146] MacQueen G.M., Frey B.N., Ismail Z. et al. Cana­dian Network for Mood and Anxiety Treatments (­CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canad. J. Psychi­atry. 2016; 61 (9): 588–603. DOI: 10.1177/0706743716660033.

[147] Syrkin A.L., Kopylov F.Yu., Popova E.A. et al. Mental disorders at different stages of the course of atrial fibrillation. Psikhicheskie rasstroystva v obshchey meditsine. 2007; (4): 10–14. (In Russ.)

[148] Сыркин А.Л., Копылов Ф.Ю., Попова Е.А. и др. Психические расстройства на разных этапах течения фибрилляции предсердий. Психич. расстройства в общ. мед. 2007; (4): 10–14.

[149] Pogosova G.V. Depression in cardiac patients: current state of the problem and treatment approaches. Kardiologiya. 2004; (1): 88–92. (In Russ.)

[150] Погосова Г.В. Депрессии у кардиологических больных: современное состояние проблемы и подходы к лечению. Кардиология. 2004; (1): 88–92.

[151] Zimakova I.E., Valimukhametova D.A., Zaikonnikova I.V. et al. Sredstvo dlya leche­niya kardialgiy i legkikh form ishemicheskoy bolezni serdtsa “mebikar”. USSR Author's Certi­ficates №366709, class A 61 K 31/12, 1972. Bull. №3 from 23.01.1985. (In Russ.)

[152] Зимакова И.Е., Валимухаметова Д.А., Заиконникова И.В. и др. Средство для лечения кардиалгий и лёгких форм ишемической болезни сердца «мебикар». Авторское свидетельство СССР №366709, кл. А 61 К 31/12, 1972. Бюлл. №3 от 23.01.1985.

[153] Vasilets L.M., Tuev A.V., Vyshenskaya A.Yu. et al. Ventricular pre-excitation syndrome and phenomena: impact of adaptol on cardiac rhythm variability and arrhythmic readiness. Kardio­logiya i serdechno-sosudistaya khirurgiya. 2011; 4 (3): 68–72. (In Russ.)

[154] Василец Л.М., Туев А.В., Вышенская А.Ю. и др. Синдром и феномен преждевременного возбуждения желудочков: влияние адаптола на вариабельность ритма сердца и аритмогенную готовность. Кардиол. и сердечно-сосуд. хир. 2011; 4 (3): 68–72.

[155] Medvedev V.Eh., Chobanu I.K., Frolova V.I. et al. The effectiveness of psychopharmacotherapy and psychotherapy in patients with cardiovascular disease. Arkhiv vnutrenney meditsiny. 2013; (5): 61–66. (In Russ.)

[156] Медведев В.Э., Чобану И.К., Фролова В.И. и др. Эффективность психофармакотерапии и психотерапии у пациентов с сердечно-сосудистыми заболеваниями. Арх. внутренней мед. 2013; (5): 61–66.

[157] VigiAccess ТМ. http://www.vigiaccess.org. (access data: 20.08.2019).

[158] VigiAccess ТМ. http://www.vigiaccess.org. (дата обращения: 20.08.2019).

[159] Prisant L.M., Spruill W.J., Fincham J.E. et al. Depression associated with antihypertensive drugs. J. Fam. Pract. 1991; 33 (5): 481–485. PMID: 1682414.

[160] Belovol A.N. Clinical pharmacology of beta-blockers in chronic heart failure. Svіt meditsini ta bіologії. 2012; (1): 7–13. (In Ukr.)

[161] Беловол А.Н. Клиническая фармакология бета-блокаторов, применяемых при хронической сердечной недостаточности. Світ медицини та біології. 2012; (1): 7–13.

[162] Waal H.J. Propranolol-induced depression. Brit. Med. J. 1967; 2: 50. DOI: 10.1136/bmj.2.5548.372-b.

[163] Cremona-Barbaro A. Propranolol and depression. Lancet. 1983; 321: 185. DOI: 10.1016/S0140-6736(83)92786-1.

[164] Nolan B.T. Acute suicidal depression associated with use of timolol. JAMA. 1982; 247: 1567. DOI: 10.1001/jama.1982.03320360019022.

[165] Pazos A., Probst A., Palacios J.M. Beta-adrenoceptor subtypes in the human brain: autoradiographic localization. Brain Res. 1985; 358: 324–328. DOI: 10.1016/0006-8993(85)90977-1.

[166] Direct evidence for an interaction of beta-adrener­gic blockers with the 5-HT receptor. Nature. 1977; 267: 289–290. DOI: 10.1038/267289a0.

[167] Koella W.P. CNS-related (side-) effects of betablo­ckers with special reference to mechanisms of action. Eur. J. Clin. Pharmacol. 1985; 28: 55–63. DOI: 10.1007/bf00543711.

[168] Daniëlle E.P., Jerry R., Rudolf A.B. et al. A review on the putative association between beta blockers and depression. Heart Failure Clin. 2011; 7: 89–99. DOI: 10.1016/j.hfc.2010.08.006.

[169] Anthony J.B., Nabeela Z., Graham D.C. et al. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: Recom­mendations for patient information. Intern. J. ­Cardiol. 2013; 168: 3572–3579. DOI: 10.1016/j.ijcard.2013.05.068.

[170] Dassylva B. Verapamil may cause depression. Canad. J. Psychiatry. 1993; 38 (4): 299–300.

[171] Wilson D.L., Ried L.D. Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. Res. Soc. Admin. Pharmac. 2012; 8 (4): 309–320. DOI: 10.1016/j.sapharm.2011.08.002.

[172] Lindberg G., Bingefors K., Ranstam J. et al. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. Brit. Med. J. 1998; 316: 741–745. DOI: 10.1136/bmj.316.7133.741.

[173] McMahon T. Bipolar affective symptoms associa­ted with use of captopril and abrupt withdrawal of pargyline and propranolol. Am. J. Psychiatry. 1985; 142 (6): 759–760. DOI: 10.1176/ajp.142.6.759.

[174] Braszko J.J., Karwowska-Polecka W., Halicka D. et al. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J. Basic Clin. ­Physiol. Pharmacol. 2003; 14 (4): 323–343. DOI: 10.1515/JBCPP.2003.14.4.323.

[175] Lechleitner M., Hoppichler F., Konwalinka G. et al. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin. Lancet. 1992; 340 (8824): 910. DOI: 10.1016/0140-6736(92)93318-H.

[176] Tatley M., Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Safety. 2007; 30: 195–201. DOI: 10.2165/00002018-200730030-00003.

[177] Fawcett J., Busch K.A., Jacobs D. et al. ­Suicide: a four-pathway clinical-biochemical model. Ann. NY Acad. Sci. 1997; 836: 288–301. DOI: 10.1016/S2215-0366(14)70222-6.

[178] You H., Lu W., Zhao S. et al. The relationship between statins and depression: a review of the literature. Expert Opin. Pharmacother. 2013; 14: 1467–1476. DOI: 10.1517/14656566.2013.803067.

[179] Conklin S.M., Harris J.I., Manuck S.B. et al. Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. Psychiatry Res. 2007; 152: 1–10. DOI: 10.1016/j.psychres.2006.10.006.

[180] Tuccori M., Lapi F., Testi A. et al. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Drug Safety. 2008; 31: 1115–1123. DOI: 10.2165/0002018-200831120-00007.

[181] Zhang X., Wen J., Zhang Z. Statins use and risk of dementia: A dose-response meta-analysis. Me­dicine (Baltimore). 2018; 97 (30): e11304. DOI: 10.1097/MD.0000000000011304.

[182] Köhler-Forsberg O., Gasse C., Berk M., Østergaard S.D. Do statins have antidepressant effects? CNS Drugs. 2017; 31 (5): 335–343. DOI: 10.1007/s40263-017-0422-3.

[183] Kalyagin A.N. Chronic heart failure: modern understanding of the problem. The use of cardiac glycosides (the message 12). Sibirskiy medi­tsinskiy zhurnal. 2007; (8): 85–89. (In Russ.)

[184] Калягин А.Н. Хроническая сердечная недостаточность: современное понимание проблемы. Использование сердечных гликозидов (сообщение 12). Сибирский мед. ж. 2007; (8): 85–89.

[185] Padfield P.L., Smith D.A., Fitzsimons E.J., McCruden D.C. Disopyramide and acute psychosis. Lancet. 1977; 1 (8022): 1152. DOI: 10.1016/S0140-6736(77)92410-2.

[186] Saravay S.M., Marke J., Steinberg M.D., Rabi­ner C.J. “Doom anxiety” and delirium in lidocaine toxicity. Am. J. Psychiatry. 1987; 144 (2): 159–163. DOI: 10.1176/ajp.144.2.159.

[187] Kahn J.K. Nifedipine-associated acute psychosis. Am. J. Med. 1986; 81 (4): 705–706. DOI: 10.1016/0002-9343(87)90745-5.

[188] Guan H., Liu Y., Daily A. et al. Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer’s disease. J. Neurosci. Res. 2009; 87 (06): 1462–1473. DOI: 10.1002/jnr.21944.

[189] Kanemitsu H., Tomiyama T., Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett. 2003; 350: 113–116. DOI: 10.1016/s0304-3940(03)00898-x.

[190] Solomon S.D., Rizkala A.R., Gong J. et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017; 5 (7): 471–482. DOI: 10.1016/j.jchf.2017.04.013.

[191] Iskandar Z.M., Lang C.C. Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients. Drugs Today. 2017; 53 (10): 545–551. DOI: 10.1358/dot.2017.53.10.2722396.

[192] De Vecchis R., Ariano C., Di Biase G., Noutsias M. Cognitive performance of patients with chronic heart fai­lure on sacubitril/valsartan: A retrospective cohort study. Herz. 2019; 44 (6): 534–540. DOI: 10.1007/s00059-018-4683-5.

[193] Whalley B., Thompson D.R., Taylor R.S. Psychological interventions for coronary heart disease: cochrane systematic review and meta-analysis. Int. J. Behav. Med. 2014; 21 (1): 109–121. DOI: 10.1007/s12529-012-9282-x.

RIGHTS & PERMISSIONS

Zhidyaevskj A.G., Mendelevich V.D., Galyautdinov G.S., Ibragimova K.R., Zakirova E.B.